Cosmo NVCMOPF +0.67%79 PS Ratio is 10.90 as of Jul. 03, 2026, which is 34% below its 10-year median of 16.44. GuruFocus rates CMOPF with a GF Score™ of 79/100 and a GF Value™ of $54.27 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 950 Drug Manufacturers companies, Cosmo NV ranks worse than 88.21% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cosmo NV's share price is $82.60.
Cosmo NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $7.58. Hence, Cosmo NV's PS Ratio for today is 10.90.
The historical rank and industry rank for Cosmo NV's PS Ratio or its related term are showing as below:
CMOPF'
s PS Ratio Range Over the Past 10 Years
Min: 3.05 Med: 16.44 Max: 39.89
Current: 10.87
During the past 13 years, Cosmo NV's highest PS Ratio was 39.89. The lowest was 3.05. And the median was 16.44.
CMOPF's PS Ratio is ranked worse than 88.21% of 950
companies
in the Drug Manufacturers industry
Industry Median: 2.315
vs CMOPF: 10.87
Cosmo NV revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Cosmo NV was -59.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -0.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 16.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 5.80% per year.
During the past 13 years, Cosmo NV's highest 3-Year average Revenue per Share Growth Rate was 55.90% per year. The lowest was -28.20% per year. And the median was -0.30% per year.
Back to Basics: PS Ratio
Cosmo NV (OTCPK:CMOPF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cosmo NV PS Ratio Related Terms
Cosmo NV PS Ratio Historical Data
* Premium members only.
The historical data trend for Cosmo NV's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Cosmo NV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cosmo NV's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cosmo NV's Share Price of today is $82.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $7.58.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cosmo NV (CMOPF) has a PS Ratio of 10.90 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cosmo NV and its competitors. This is 34% below median its historical median of 16.44. Over the past decade, Cosmo NV's PS Ratio has ranged from 3.05 to 39.89. According to the industry distribution chart, Cosmo NV ranks #838 out of 950 companies in the Drug Manufacturers industry, placing it in the top 88.2%.
Is Cosmo NV's PS Ratio too high?
Cosmo NV's current PS Ratio of 10.90 is 34% below median its 10-year median of 16.44. Over the past 10 years, this metric has ranged from a low of 3.05 to a high of 39.89. The Drug Manufacturers industry median PS Ratio is 2.32. Cosmo NV's value of 10.90 is 370.8% above this industry median. Based on the distribution chart, Cosmo NV ranks #838 out of 950 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cosmo NV has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #838 out of 950 companies for PS Ratio. This places Cosmo NV in the lower half of its industry. The industry median PS Ratio is 2.32. Cosmo NV's value of 10.90 is 370.8% above this benchmark. Historically, Cosmo NV's own PS Ratio has ranged from 3.05 to 39.89 over the past decade. While the company's 10-year median is 16.44 vs. the industry median of 2.32, Cosmo NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current PS Ratio of 10.90 is 370.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current PS Ratio is 10.90, which is 34% below median its own 10-year median of 16.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.27, compared to a current price of $82.60 — trading 52.2% above its estimated fair value. The current PS Ratio is 10.90, which is 34% below median its 10-year median of 16.44 and 370.8% above the Drug Manufacturers industry median of 2.32. Cosmo NV's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current PS Ratio is 10.90 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $82.60 is trading 52.2% above its estimated GF Value™ of $54.27.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
PS Ratio: 10.90 (34% below median its 10-year median of 16.44)
GF Value™: $54.27 vs. price of $82.60 (52.2% above fair value)
Industry Position: 370.8% above the Drug Manufacturers median (#838 of 950)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
79GF Score
Get the complete analysis for CMOPF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
